NCT03304054View on ClinicalTrials.gov

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

PHASE3CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

January 31, 2020

Study Completion Date

March 15, 2020

Conditions
Myasthenia Gravis, Generalized
Interventions
DRUG

Amifampridine Phosphate

tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day

DRUG

Placebo Oral Tablet

tablets matching amifampridine phosphate, 3 to 4 times a day

Trial Locations (2)

19104

Univerity of Pennsylvania, Philadelphia

44195

Cleveland Clinic, Cleveland

Sponsors
All Listed Sponsors
lead

Catalyst Pharmaceuticals, Inc.

INDUSTRY

NCT03304054 - Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG | Biotech Hunter | Biotech Hunter